Acadian Asset Management’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $459K | Sell |
1,964,141
-254,074
| -11% | -$59.4K | ﹤0.01% | 1157 |
|
|
2025
Q1 | $424K | Buy |
2,218,215
+1,707,999
| +335% | +$326K | ﹤0.01% | 1110 |
|
|
2024
Q4 | $269K | Buy |
+510,216
| New | +$269K | ﹤0.01% | 1202 |
|
|
2023
Q3 | – | Sell |
-358,010
| Closed | -$329K | – | 1622 |
|
|
2023
Q2 | $329K | Buy |
358,010
+47,085
| +15% | +$43.3K | ﹤0.01% | 1158 |
|
|
2023
Q1 | $332K | Sell |
310,925
-214,569
| -41% | -$229K | ﹤0.01% | 1143 |
|
|
2022
Q4 | $760K | Buy |
525,494
+413,926
| +371% | +$599K | ﹤0.01% | 914 |
|
|
2022
Q3 | $116K | Buy |
111,568
+97,980
| +721% | +$102K | ﹤0.01% | 1330 |
|
|
2022
Q2 | $23K | Sell |
13,588
-30,620
| -69% | -$51.8K | ﹤0.01% | 1600 |
|
|
2022
Q1 | $91K | Buy |
+44,208
| New | +$91K | ﹤0.01% | 1379 |
|
|
2021
Q1 | – | Sell |
-301,408
| Closed | -$1.63M | – | 2035 |
|
|
2020
Q4 | $1.63M | Buy |
+301,408
| New | +$1.63M | 0.01% | 827 |
|
|
2019
Q3 | – | Sell |
-42,517
| Closed | -$170K | – | 1864 |
|
|
2019
Q2 | $170K | Buy |
42,517
+23,143
| +119% | +$92.5K | ﹤0.01% | 1263 |
|
|
2019
Q1 | $83K | Sell |
19,374
-18,704
| -49% | -$80.1K | ﹤0.01% | 1566 |
|
|
2018
Q4 | $219K | Buy |
+38,078
| New | +$219K | ﹤0.01% | 1093 |
|
|
2018
Q2 | – | Sell |
-27,508
| Closed | -$309K | – | 1673 |
|
|
2018
Q1 | $309K | Buy |
27,508
+11,397
| +71% | +$128K | ﹤0.01% | 965 |
|
|
2017
Q4 | $108K | Sell |
16,111
-9,011
| -36% | -$60.4K | ﹤0.01% | 1076 |
|
|
2017
Q3 | $206K | Buy |
+25,122
| New | +$206K | ﹤0.01% | 912 |
|